summari upgrad outperform market
perform believ compani late stage pipelin
help acceler growth next sever quarter
begin may addit compani done
better job past year manag street expect
fact exceed consensu ep estim averag
past four quarter lastli current trade
discount larg cap med-tech peer group averag
vs estim believ gap
close pipelin materi top-line growth acceler
rais revenu estim
respect due greater share captur
micra av leadless pacemak ad surgic robot
model launch ad back renal denerv
estim model also rais
ep estim
respect increas price target assum
ep estim
see acceler growth stori trade
steep discount peer forecast mdt organ growth
acceler cours
addit forecast mdt organ growth acceler
may main
driver acceler micra av leadless
pacemak surgic robot platform reveal linq
diabet pump next gener interstim
devic figur present overview mdt pipelin
reveal linq like come soon reveal linq mdt highli
success implant loop record ilr detect
monitor arrhythmia linq post sale
grew ex-fx despit new competit abt confirm rx
plan launch next gener reveal linq
given indic investor meet may
linq launch would occur believ
launch like earli
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani data secur llc estim reuter
continu previou page
earli feedback physician linq posit compar linq linq
indic smaller size see figur check suggest linq provid linq franchis
boost sale due longev smaller size better accuraci current model
world-wide linq sale see potenti
upsid estim base initi feedback weve receiv linq
surgic robot unveil fall track launch mdt robot assist
surgeri ra platform remain track commerci launch april
manag confirm call system first launch oversea also note
plan unveil system investor event fall event dedic robot
platform includ feedback surgeon user updat call encourag
impli platform closer commerci held sever submiss meet
regulatori bodi around world earli includ fda provid
timelin us launch platform use surgeon note
initi experi respect system perform workflow posit compani
share limit detail due competit reason like provid increment detail investor
surgic robot revenu modest note call surgic
robot revenu modest earli launch first year meaning
revenu contribut like time surgic robot launch slip
past analyst day note revenu surgic robot platform could
add mitg minim invas therapi group growth translat estim
sale one-year delay result final softwar hardwar integr
test took longer anticip
surgic robot platform like focus drive util lower per-procedur
cost mdt surgic robot platform key driver compani advanc mi minim
invas surgeri platform largest growth opportun within mitg previous note
surgic procedur perform annual current area focu well still
perform open approach time believ open procedur could
convert mi lap robotic-assist surgeri note even convers would
translat increment opportun see figur believ well-
posit capit opportun give expertis advanc instrument stapler
licens surgic robot technolog began robot invest
januari compani largest strateg invest mitg compani
employe three locat dedic robot platform june analyst day
believ fast expand compani surgic robot built technolog licens
german aerospac center dilig suggest platform featur multi-quadr
system lightweight robot arm flexibl joint sensit similar dlr space robot enabl
precis real-tim feedback surgeon robot arm like place pedest
table-mount allow mobil easili move room-to-room like featur
small footprint similar cmr surgic versiu platform consol featur monitor
vision surgic space requir surgeon look scope da vinci
system surgeon like use joystick-lik control manipul instrument end
robot arm goal maintain enhanc surgeon current workflow laparoscopi surgeri
allow surgeon oper difficult-to-access space easi instrument articul
check suggest mdt system may easi set-up requir surgeon manual
re-align robot arm directli trocar da vinci requir surgeri
figur ra
robot assist surgeri ra still earli inning adopt ra market notabl
under-penetrated account less global procedur includ less us
believ much room addit player check compani
commentari suggest aim bring low-cost easili upgrad solut similar
laparoscopi market drive util reduc econom barrier associ robot
surgeri goal offer natur step forward versu laparoscopi drive util
instrument set per-procedur cost lower believ compani look treat wide
array procedur includ gynecolog urolog gener surgeri instrument
updat model surgic robot platform given proxim launch
updat model includ revenu surgic robot platform current model
world-wide sale time
view revenu estim conserv reason given havent seen final
version system receiv detail feedback system surgeon given
isrg entrench posit us believ greater success outsid us cost
greater barrier adopt robot compar us robot penetr much lower
micra vr help take share pacemak market micra leadless pacemak
launch outsid us april us april current version micra
vr singl chamber pacemak suitabl pacemak patient estim
micra vr help captur bp share us pacemak market sinc product
receiv reimburs march help take share outsid us sinc
launch estim micra sale current annual around
micra av help captur addit pacemak share plan launch new version
micra av late earli spring expand elig patient popul
pacemak patient three time current address market base posit
physician feedback weve receiv well earli experi micra vr believ launch
micra av help captur addit share pacemak market asp micra roughli
three time typic pacemak march micra receiv posit nation
coverag decis ncd
micra av could add bp overal growth use share captur
pacemak market behind micra vr estim micra av could add roughli per year
ww pacemak sale growth overal growth year fiscal fiscal
analysi base mdt share captur sinc micra vr reimburs ou
share captur sinc micra vr launch abroad assumpt micra av repres
increment market opportun micra vr exhibit
exhibit overview mdt micra program
exhibit micra av analysi potenti impact growth
mdt renal denerv program like repres upsid street estim recal januari
announc simplic htn pivot renal denerv trial miss primari
endpoint activ arm show enough differ sham control arm base
learn htn trial made number chang technolog procedur
techniqu patient select trial design compani conduct two pilot trial spyral htn-
spyral htn-off confirm chang address issu htn trial
 pacemak share ttm micra vr reimburs pacemak market share captur impli approx annual impact micra av pacemak share ttm ou micra vr pacemak market share captur impli approx annual impact micra av annual impact micra av growth impact overal compani report secur llc estimatesttm trail twelv month medtron plc
pivot trial like present spring april announc
receiv approv fda begin us pivot trial compani symplic spyral renal
denerv devic patient hypertens high blood pressur spyral htn pivot trial
part broader spyral htn clinic program includ spyral htn-off spyral
htn-on pilot studi spyral htn pivot trial random sham-control studi
enrol patient site across europ australia japan trial
investig blood pressur lower effect safeti absenc anti-hypertens
medic off-m patient trial primari efficaci safeti endpoint blood
pressur month incid major advers event one-month post-random
roll-in patient pilot studi disclos plan present
pivot data spring believ compani target american colleg
cardiolog march base spyral htn-off pilot studi result believ
high likelihood pivot trial posit
expand spyral htn trial support approv adopt addit spyral
htn pivot trial also increas sampl size spyral htn trial approxim
patient patient trial continu enrol expect complet
novemb accord clinicaltri gov believ plan use expand trial
support approv commerci popul largest initi
commerci opportun view patient uncontrol three drug
spyral htn-on data show signific blood pressur reduct patient
still take blood pressur medic may month result mdt spyral
htn-on studi present late break clinic trial pcr pari cours
revascular result studi simultan publish lancet high-profil
medic journal spyral htn on-m studi compar mdt symplic spyral sham
procedur uncontrol hypertens patient take antihypertens medic month data
show group statist signific reduct blood pressur
cohort averag declin hg offic systol blood pressur mm hg differ vs
patient control arm sham procedur offic diastol blood pressur patient
declin averag hg differ hg vs control group hour
systol ambulatori blood pressur declin averag hg hg differ vs
control arm hour diastol ambulatori blood pressur declin averag
hg hg differ vs control group
spyral htn-off pilot data show signific blood pressur reduct
patient blood pressur medic august result mdt spyral htn-off
studi present late break clinic trial esc european societi cardiolog
meet barcelona simultan publish lancet spyral htn off-m studi
compar sham procedur uncontrol hypertens patient blood pressur medic
interim month data present esc show group statist
signific reduct blood pressur cohort averag declin hg offic
systol blood pressur mm hg differ vs patient control arm sham procedur
offic diastol blood pressur patient declin averag hg differ
hg vs control group hour systol ambulatori blood pressur declin
averag hg hg differ vs control arm hour diastol
ambulatori blood pressur declin averag hg hg differ vs control
group may disappoint absolut level blood pressur
reduct import rememb patient spyral htn-off moder
hypertens therefor treatment effect expect lower seen
earlier studi earlier trial enrol patient sever hypertens
ad sale model prior neg result simplic htn trial
januari forecast sale year ramp year
commerci disappoint trial result subsequ remov relat sale
model given confid pivot trial result proxim data
present updat model includ modest revenu start
updat model assum sale
diabet franchis darkest dawn believ investor sentiment toward mdt diabet
franchis current quit neg compani fallen behind competit insulin
pump continu glucos monitor cgm base recent check expect upcom
american diabet associ ada meet come weekend posit tndm new control
iq pump platform pivot data schedul present june pt howev think
updat investor meet june give investor confid close
gap insulin pump cgm competitor next month
diabet pipelin updat ada like posit announc call
may plan file non-adjunct indic cgm sensor earli fy
impli approv around approv enabl mdt pump access
medicar market account diabet patient addit plan launch
advanc hybrid close loop ahcl system late accord
featur next-gener algorithm design improv time rang accord
clinicaltri gov recent initi pivot trial next gener cgm
algorithm new sensor algorithm success new studi would expect transfer
algorithm next gener uniti cgm platform previou present state
fulli dispos requir calibr last day see figur recent updat
diabet pipelin unclear time exactli abl launch
best guess around year end earli believ platform competit
compet cgm devic investor may appreci
advanc technolog treatment diabet
advanc technolog treatment diabet
gener interstim help close competit gap background mdt interstim ii
current approv sacral neuromodul snm devic overact bladder oab
us recent receiv approv snm devic europ expect approv us
later year axnx devic advantag mdt interstim smaller recharg
user friendli like fulli mri-compat upon approv us plan
launch next-gener snm devic oab earli fiscal year start may
 europ mdt next-gener system recharg cc size vs cc
full-bodi mri compat tesla mri system accord compani base
timelin expect competit disadvantag quarter
model interstim sale
figur overview mdt pipelin
 oct april linq icdmicra ar ddrcorevalveevolut pro size includ av late approv symplic spyral renal denervationmvadev-icd start us pivot trial earli risk indic expans bicuspidintrepid tmvrfulli implant hvad mvadtavr confidasheath dcb -avf gener tavi horizonadmir dcb btkchina sfa gener resolut onyx gener cryoballoondiamondtemp ablat puls field ablationrobot assist surgeri ra platform hemodialysi ra instrument enhanc stapler multitherapi blood purif capnostream oem monitorendo-bronchi ablat cathetermicrostream stapl line gener dialyzeraccurian nerv ablat ulat fy mri-compat microstimul pelvic health earli gener stratospher mount dbsent power consolenim primari cell db intrasaccular deviceinfus clinic indic expansionmida drill platforminject tibial nerv saber tlifharmoni sensor sensor ject uniti glucos hybrid close loop cloud person time coachingsugar iq dose assist set extend wearenvis timenon-adjunct claimenvis earn call compani report secur llcrestor therapi group vascular group cvg minim invas therapi group mitg post-april plc
price target
price target assum cy cash ep estim risk
includ weak key end market greater share loss model delay product
believ acceler growth stori trade steep discount peer organ
growth acceler come quarter due new product launch micra av
surgic robot linq diabet pump next gener interstim
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
